## ICMJE DISCLOSURE FORM

Date: 20.2.2023

Your Name: Dr.Abdulaziz Babaier

Manuscript Title: Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?

Manuscript number (if known): ATM-23-903

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	x_None	
2	Grants or contracts from any entity (if not indicated in item #1 above).	Time frame: past _xNone	36 months
3	Royalties or licenses	x_None	
4	Consulting fees	xNone	

le sp	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	_xNone					
	educational events						
6	Payment for expert	_xNone					
	testimony						
7	Support for attending meetings and/or travel	xNone					
	eetinge ana, e. e.are.						
8	Patents planned, issued or	xNone					
	pending						
9	Participation on a Data	x None					
9	Safety Monitoring Board or	_xNone					
	Advisory Board						
10	Leadership or fiduciary role	xNone					
	in other board, society,						
	committee or advocacy group, paid or unpaid						
11	Stock or stock options	_xNone					
40							
12	Receipt of equipment,	xNone					
	materials, drugs, medical writing, gifts or other services						
13	Other financial or non-	xNone					
	financial interests						
Please summarize the above conflict of interest in the following box:							
Γ.							
None.							

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.

## ICMJE DISCLOSURE FORM

Date: 20.2.2023

Your Name: Dr. Prafull Ghatage

Manuscript Title: Among patients with advanced ovarian carcinoma, who benefits from bevacizumab the most?

Manuscript number (if known): ATM-23-903

In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.

The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> <u>manuscript only</u>.

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)		
	Time frame: Since the initial planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	xNone			
	Time frame: past 36 months				
2	Grants or contracts from any entity (if not indicated in item #1 above).	_xNone			
3	Royalties or licenses	x_None			
4	Consulting fees	xNone			

le sp	Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or	_xNone					
	educational events						
6	Payment for expert	_xNone					
	testimony						
7	Support for attending meetings and/or travel	xNone					
	eetinge ana, e. e.are.						
8	Patents planned, issued or	xNone					
	pending						
9	Participation on a Data	x None					
9	Safety Monitoring Board or	_xNone					
	Advisory Board						
10	Leadership or fiduciary role	xNone					
	in other board, society,						
	committee or advocacy group, paid or unpaid						
11	Stock or stock options	_xNone					
40							
12	Receipt of equipment,	xNone					
	materials, drugs, medical writing, gifts or other services						
13	Other financial or non-	xNone					
	financial interests						
Please summarize the above conflict of interest in the following box:							
Γ.							
None.							

Please place an "X" next to the following statement to indicate your agreement:

\_\_X\_ I certify that I have answered every question and have not altered the wording of any of the questions on this form.